Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:metformin
gptkb:ertugliflozin |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A10BD23
|
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to components |
| gptkbp:drugClass |
antidiabetic
biguanide SGLT2 inhibitor |
| https://www.w3.org/2000/01/rdf-schema#label |
Segluromet
|
| gptkbp:marketedAs |
gptkb:Pfizer
gptkb:Merck_&_Co. |
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:sideEffect |
urinary tract infection
lactic acidosis genital mycotic infection |
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:bfsParent |
gptkb:MRK
gptkb:Steglatro |
| gptkbp:bfsLayer |
5
|